<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>29094</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1186/1471-2350-2-1</infon><infon key="article-id_pmc">29094</infon><infon key="article-id_pmid">11180758</infon><infon key="article-id_publisher-id">1471-2350-2-1</infon><infon key="fpage">1</infon><infon key="journal-title">BMC Medical Genetics</infon><infon key="lpage">1</infon><infon key="name_0">surname:Ban;given-names:Yoshiyuki</infon><infon key="name_1">surname:Tozaki;given-names:Teruaki</infon><infon key="name_2">surname:Taniyama;given-names:Matsuo</infon><infon key="name_3">surname:Tomita;given-names:Motowo</infon><infon key="name_4">surname:Ban;given-names:Yoshio</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">2</infon><infon key="year">2001</infon><offset>0</offset><text>Lack of association between estrogen receptor &#946; dinucleotide repeat polymorphism and autoimmune thyroid diseases in Japanese patients</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>137</offset><text>What is the background on this?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>148</offset><text>A complex interaction between predisposing genes and environmental triggers appears to be responsible for autoimmune thyroid diseases (AITDs), including Graves' disease and Hashimoto's thyroiditis, with AITD susceptibility conferred by genes in the human leukocyte antigen (HLA) and unlinked genes such as the CTLA-4 gene. We identified a dinucleotide (CA)n repeat polymorphism in an ER gene flanking region at human chromosome 14q23-24.1 in patients and normal subjects.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1057</offset><text>What are the outcomes?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1065</offset><text>All 133 patients with GD, 114 patients who had HT, and the majority of 179 controls were found to have fourteen different alleles. The allELESESE through allELLE14 (ranging from 18 to 30) revealed no significant differences in the distributions of EER-alleleS between patient groups and controls. A recent study indicated a significant relation between an allEL*9 and BMD in postmenopausal Japanese women, but there was no statistically significant interaction between this all&#232;le and distal radius.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1708</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1720</offset><text>The current findings do not support an association between the ER microsatellite marker and AITD in the Japanese population. Furthermore, we propose that the accuracy of the results indicates that it is not highly associated with GD or osteoporosis risk.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2014</offset><text>The relationship between genetic polymorphisms (GPRMs) and autoimmune thyroid disorders is well established. However, the role of GPRMs in the pathogenesis of autoimmune thyroid disorders is still poorly understood. The aim of this study is to compare the effect of the GPRM 1, 2, and 3 variants, rs206849 and rs9283894, on autoimmune thyroid disease in Japanese patients.

Methods: We performed a prospective, population-based cohort study in Japan to evaluate the association between the GPRM 1, 2, and 3 variants and autoimmune thyroid disease.

Results: The GPRM 1, 2, and 3 variants significantly affected the risk of autoimmune thyroid disease (adjusted OR 0.98, 95% CI 0.88 to 1.00, P</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2025</offset><text>A dinucleotide (TA)n repeat polymorphism upstream of the human estrogen receptor (ER)  gene was identified in 130 patients with Graves' disease, 93 patientswith Hashimoto's thyroiditis (HT), and 190 control subjects. This study investigated 17 different alleles in normal subjects and found no significant differences in the distribution of ER allELEs.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2525</offset><text>Complex interplay between genetic and environmental factors plays a crucial role in the pathogenesis of AITDs. Generating genes within and outside of HLA, including CTLA-4, has been associated with an ER gene polymorphism. This has also been observed in connection with some variant ERT genotypes linked to various diseases.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3072</offset><text>A second type of human ER (ER) gene was recently identified, located at human-chromosome 14q23-24.1, where the abnormality in DNA copy number in bone disorders is frequently observed. This locus was found to be similar to and distinct from an AEAE counterpart (GD-1) on chromophore 14Q31. We investigated whether a CA or other EN repeat polymorphism could contribute to osteoporosis in patients with AITDs and in normal subjects.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>4208</offset><text>Results and discussion</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>4231</offset><text>Allele frequencies of ER&#946; gene microsatellite polymorphism in patients and controls</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>4318</offset><text>In general, estrogen action is thought to be mediated by ER, a member of the nuclear receptor superfamily. Recent studies have shown the presence of ERs on cells involved in immune response, namely thymocyte, macrophages and endothelial cells. Particular attention has been focused on the dose-dependent influence of estrogen on immune response, which appears to be related to the clinical symptoms of autoimmunity (i.e., the effects of pregnancy or oral contraceptive pills). The influence of estrogens on cytokine production by target cells, through interference with their transcriptional activity, has also been the focus of various studies. The effect of estrogens on the expression of the proto-oncogenes and oncosuppressor genes involved in programmed cell death (apoptosis) might also be relevant to human autoimmunity; in particular, the uncontrolled synovial lining cell hyperplasia associated with rheumatoid arthritis and the prolonged T-cell survival in systemic lupus erythematosus may be important.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>5332</offset><text>The ER&#946; gene, isolated by Mosselman et al., has 96% conserved amino acid residues in the DNA binding domain and 58% conserved residues in the ligand binding domain compared with the respective residues for ER&#945;. The ER&#946; microsatellite polymorphism we analyzed in the present study has been recently characterized by Tsukamoto et al.. High heterozygosity (0.93) makes this polymorphism a useful marker in the genetic study of disorders affecting female endocrine systems. Indeed, an association of some ER&#946; genotypes with osteoporosis has been reported. Thus, we investigated the relation between a dinucleotide (CA)n repeat polymorphism lying upstream of the human ER gene and AITDs.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6028</offset><text>Fourteen different alleles were found in 133 patients with GD, 114 patients with HT, and 179 controls subjects. The various alleles were designated as allele*1 through allele*14 according to their sizes, which ranged from 150 bp (containing 18 CA repeats with a 114 bp segment of amplified flanking sequences) to 176 bp (30 CA repeats). The distribution of ER&#946; alleles in the three groups is shown in Table 1. The allelic frequencies in our control population are in agreement with those previously published. Allele frequencies in our GD patients and our control subjects did not differ significantly (&#935;2 = 11.71, 13 degrees of freedom, P = 0.55). Allele frequencies in our HT patients and our control subjects also did not differ significantly (&#935;2 = 16.05, 13 degrees of freedom, P = 0.25). According to our power calculations, we could exclude both associations with relative risk &gt; 0.5 for the groups analyzed in Table 1 (GD patients vs. control subjects) and associations with relative risk &gt; 0.3 for the groups analyzed in Table 1 (HT patients vs. control subjects).</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>7108</offset><text>Allele frequencies of the ER&#946; gene polymorphism in patients with AITDs and in control subjects</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center"&gt;Graves' disease&lt;/td&gt;&lt;td align="center"&gt;Hashimoto's thyroiditis&lt;/td&gt;&lt;td align="center"&gt;Controls&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;ER&#946; polymorphism&lt;/td&gt;&lt;td align="center"&gt;n=133, (266 alleles)&lt;/td&gt;&lt;td align="center"&gt;n=114, (228 alleles)&lt;/td&gt;&lt;td align="center"&gt;n=179, (358 alleles)&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;1&lt;/td&gt;&lt;td align="center"&gt;8 (3.0%)&lt;/td&gt;&lt;td align="center"&gt;6 (2.6%)&lt;/td&gt;&lt;td align="center"&gt;11 (3.1%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;2&lt;/td&gt;&lt;td align="center"&gt;0 (0%)&lt;/td&gt;&lt;td align="center"&gt;2 (0.9%)&lt;/td&gt;&lt;td align="center"&gt;1 (0.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;3&lt;/td&gt;&lt;td align="center"&gt;0 (0%)&lt;/td&gt;&lt;td align="center"&gt;3 (1.3%)&lt;/td&gt;&lt;td align="center"&gt;1 (0.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;4&lt;/td&gt;&lt;td align="center"&gt;6 (2.3%)&lt;/td&gt;&lt;td align="center"&gt;4 (1.8%)&lt;/td&gt;&lt;td align="center"&gt;14 (3.9%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;5&lt;/td&gt;&lt;td align="center"&gt;57 (21.4%)&lt;/td&gt;&lt;td align="center"&gt;54 (23.7%)&lt;/td&gt;&lt;td align="center"&gt;87 (24.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;6&lt;/td&gt;&lt;td align="center"&gt;20 (7.5%)&lt;/td&gt;&lt;td align="center"&gt;19 (8.3%)&lt;/td&gt;&lt;td align="center"&gt;24 (6.7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;7&lt;/td&gt;&lt;td align="center"&gt;15 (5.6%)&lt;/td&gt;&lt;td align="center"&gt;6 (2.6%)&lt;/td&gt;&lt;td align="center"&gt;21 (5.9%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;8&lt;/td&gt;&lt;td align="center"&gt;32 (12.0%)&lt;/td&gt;&lt;td align="center"&gt;29 (12.7%)&lt;/td&gt;&lt;td align="center"&gt;36 (10.1%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;9&lt;/td&gt;&lt;td align="center"&gt;18 (6.8%)&lt;/td&gt;&lt;td align="center"&gt;23 (10.1%)&lt;/td&gt;&lt;td align="center"&gt;32 (8.9%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;10&lt;/td&gt;&lt;td align="center"&gt;74 (27.8%)&lt;/td&gt;&lt;td align="center"&gt;44 (19.3%)&lt;/td&gt;&lt;td align="center"&gt;87 (24.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;11&lt;/td&gt;&lt;td align="center"&gt;27 (10.2%)&lt;/td&gt;&lt;td align="center"&gt;30 (13.2%)&lt;/td&gt;&lt;td align="center"&gt;31 (8.7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;12&lt;/td&gt;&lt;td align="center"&gt;9 (3.4%)&lt;/td&gt;&lt;td align="center"&gt;6 (2.6%)&lt;/td&gt;&lt;td align="center"&gt;7 (2.0%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;13&lt;/td&gt;&lt;td align="center"&gt;0 (0%)&lt;/td&gt;&lt;td align="center"&gt;1 (0.4%)&lt;/td&gt;&lt;td align="center"&gt;5 (1.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;allele &lt;sup&gt;*&lt;/sup&gt;14&lt;/td&gt;&lt;td align="center"&gt;0 (0%)&lt;/td&gt;&lt;td align="center"&gt;1 (0.4%)&lt;/td&gt;&lt;td align="center"&gt;1 (0.3%)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>7206</offset><text>	Graves' disease	Hashimoto's thyroiditis	Controls	 	ER&#946; polymorphism	n=133, (266 alleles)	n=114, (228 alleles)	n=179, (358 alleles)	 	allele *1	8 (3.0%)	6 (2.6%)	11 (3.1%)	 	allele *2	0 (0%)	2 (0.9%)	1 (0.3%)	 	allele *3	0 (0%)	3 (1.3%)	1 (0.3%)	 	allele *4	6 (2.3%)	4 (1.8%)	14 (3.9%)	 	allele *5	57 (21.4%)	54 (23.7%)	87 (24.3%)	 	allele *6	20 (7.5%)	19 (8.3%)	24 (6.7%)	 	allele *7	15 (5.6%)	6 (2.6%)	21 (5.9%)	 	allele *8	32 (12.0%)	29 (12.7%)	36 (10.1%)	 	allele *9	18 (6.8%)	23 (10.1%)	32 (8.9%)	 	allele *10	74 (27.8%)	44 (19.3%)	87 (24.3%)	 	allele *11	27 (10.2%)	30 (13.2%)	31 (8.7%)	 	allele *12	9 (3.4%)	6 (2.6%)	7 (2.0%)	 	allele *13	0 (0%)	1 (0.4%)	5 (1.4%)	 	allele *14	0 (0%)	1 (0.4%)	1 (0.3%)	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>7921</offset><text>The number of subjects is shown with the corresponding percentage in parentheses.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>8003</offset><text>Associations of ER&#946; gene microsatellite polymorphism with distal radius BMD and biochemical markers of bone turnover</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8123</offset><text>Ogawa et al. demonstrated that, when they separated postmenopausal Japanese women into two groups bearing at least one allele*9 (26 CA repeat) and those who did not, the former subjects had significantly higher Z score of L2-4 BMD. Thus, Z score of distal radius BMD and bone turnover markers in 92 female GD patients in remission were compared between the groups (Table 2). There was no significant difference of the Z score of distal radius BMD and bone turnover markers between the groups.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>8616</offset><text>Comparison of background and biochemical data of GD patients in remission between the two groups of genotype</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center" colspan="3"&gt;Genotype&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan="3"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;Items&lt;/td&gt;&lt;td align="center"&gt;I (-)&lt;/td&gt;&lt;td align="center"&gt;I (+)&lt;/td&gt;&lt;td align="center"&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;Subjects&lt;/td&gt;&lt;td align="center"&gt;81&lt;/td&gt;&lt;td align="center"&gt;11&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Age&lt;/td&gt;&lt;td align="center"&gt;55.0 &#177; 11.1&lt;/td&gt;&lt;td align="center"&gt;59.1 &#177; 10.6&lt;/td&gt;&lt;td align="center"&gt;n.s&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Radius BMD (Z-score)&lt;/td&gt;&lt;td align="center"&gt;0.104 &#177; 1.677&lt;/td&gt;&lt;td align="center"&gt;0.714 &#177; 1.313&lt;/td&gt;&lt;td align="center"&gt;n.s&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;S-bone type ALP (IU/L)&lt;/td&gt;&lt;td align="center"&gt;71.3 &#177; 45.0&lt;/td&gt;&lt;td align="center"&gt;74.2 &#177; 34.5&lt;/td&gt;&lt;td align="center"&gt;n.s.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;S-osteocalcin (ng/mL)&lt;/td&gt;&lt;td align="center"&gt;6.3 &#177; 2.8&lt;/td&gt;&lt;td align="center"&gt;5.1 &#177; 2.3&lt;/td&gt;&lt;td align="center"&gt;n.s.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;U-total hydroxyproline&lt;/td&gt;&lt;td align="center"&gt;18.6 &#177; 8.8&lt;/td&gt;&lt;td align="center"&gt;19.9 &#177; 5.3&lt;/td&gt;&lt;td align="center"&gt;n.s.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;(nmol/mmol creatinine)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;U-total deoxypyridinoline&lt;/td&gt;&lt;td align="center"&gt;5.0 &#177; 2.2&lt;/td&gt;&lt;td align="center"&gt;6.4 &#177; 3.4&lt;/td&gt;&lt;td align="center"&gt;n.s.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;(nmol/mmol creatinine)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>8725</offset><text>	Genotype	 			 	Items	I (-)	I (+)	P value	 	Subjects	81	11		 	Age	55.0 &#177; 11.1	59.1 &#177; 10.6	n.s	 	Radius BMD (Z-score)	0.104 &#177; 1.677	0.714 &#177; 1.313	n.s	 	S-bone type ALP (IU/L)	71.3 &#177; 45.0	74.2 &#177; 34.5	n.s.	 	S-osteocalcin (ng/mL)	6.3 &#177; 2.8	5.1 &#177; 2.3	n.s.	 	U-total hydroxyproline	18.6 &#177; 8.8	19.9 &#177; 5.3	n.s.	 	(nmol/mmol creatinine)				 	U-total deoxypyridinoline	5.0 &#177; 2.2	6.4 &#177; 3.4	n.s.	 	(nmol/mmol creatinine)				 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>9153</offset><text>S, serum; U, urine; BMD, bone mineral density; ALP, alkaline phosphatase; n.s., not significant. Data are means &#177; SD except where noted.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>9291</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>9303</offset><text>We found no evidence of a link between ER gene polymorphisms in its flanking region and AITDs, but this does not necessarily exclude the totality of the polynomial (other) genes within the SER gene; limitations on using microsatellite markers with multiple allleles suggest that our results may reflect 'vast diversity in the genetic backgrounds of AITBs' which require further analysis in broader patient populations; however, we also postulate that the extent of pathogenicity associated to osteopovaries in relation to these two conditions for expressing an</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>10164</offset><text>Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10186</offset><text>Materials and methods used in this paper follow closely on the ones described in a paper we have already published.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10302</offset><text>Subjects</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10311</offset><text>One hundred and thirty-three unrelated Japanese women with GD and 114 unrelated Japanese women with HT participated in this study. GD was diagnosed from clinical symptoms and biochemical confirmation of hyperthyroidism, including diffuse goiter, ophthalmopathy, elevated radioactive iodine uptake, and elevated thyroid hormone levels. HT patients had documented clinical and biochemical hypothyroidism requiring thyroid hormone replacement therapy and showed autoantibodies against thyroid peroxidase with or without antibodies against thyroglobulin. Remission of GD is defined as follows: both thyrotropin receptor antibody (TRAb) and thyroid-stimulating antibody (TSAb) in a negative range for 6 months, and a subsequent relatively stable euthyroid state over at least 6 months after cessation of antithyroid drug treatment. Remission ranged from 0.5 to 22.0 years. The effect of the ER&#946; microsatellite polymorphism on BMD in the distal radius and biochemical markers of bone turnover were investigated in the 92 GD patients optional in remission (age range, 47 to 78 years), none of whom had been treated with radioiodine, surgery, or drugs that could affect bone turnover or BMD prior to the study. One hundred and seventy-nine unrelated Japanese women without clinical evidence or family history of any autoimmune diseases were selected as normal control subjects. All study participants lived in the Tokyo metropolitan area. The research protocol was approved by the ethics committee of Showa University hospital, and informed consent was obtained from all patients and controls.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>11900</offset><text>Measurement of biochemical markers</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11935</offset><text>Blood and urine samples were collected early in the morning after an overnight fast. Both serum and urine were stored at -70&#176;C until assayed. Serum concentration of bone alkaline phosphatase (B-ALP) was measured by densitometric scanning following polyacrylamide disc gel electrophoresis (PAGE). Osteocalcin (OC) was measured in serum with an IRMA. Materials for both assays were obtained from Mitsubishi Kagaku BCL (Tokyo, Japan). Intra- and interassay coefficients of variation were less than 10%. Urinary hydroxyproline (Hp) and deoxypyridinoline (Dpyr) were measured with high-performance liquid chromatography (HPLC; Japan Spectroscopic, Tokyo, Japan). Intra-assay coefficients of variation were less than 2.0% for Hp and 5.8% for Dpyr. Interassay coefficients of variation were less than 0.2% for Hp and 6.8% for Dpyr. Values of urinary Hp and Dpyr were corrected for urinary creatinine concentration, which was measured with an autoanalyzer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>12885</offset><text>Bone mineral density analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12915</offset><text>BMD was measured at the distal one third of the left radius with dual energy X-ray absorptiometry (DEXA; DTX-200, Osteometer, Copenhagen, Denmark). With this equipment, coefficients of variation in our laboratory were 1.0%. BMD was expressed as a Z-score representing the number of standard deviations (SDs) by which a value deviated from the mean BMD in 4095 healthy Japanese female controls aged 20 to 90 years.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>13329</offset><text>Determination of microsatellite polymorphism by polymerase chain reaction</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13403</offset><text>Genomic DNA was isolated from whole blood with a Genomix kit (Talent, Trieste, Italy). Microsatellite marker loci were typed with fluorescence-based methods. Polymerase chain reaction (PCR) was performed with oligonucleotide primers designed to amplify a polymorphic (CA)n repeat in the flanking region of the human ER&#946; gene. PCR was performed in a total volume of 20 &#956;l of the following mixture: 100 ng of human genomic DNA, 5 pmol of each primer (Cy-5'-GGTAAACCATGGTCTGTACC-3' and 5'-AACAAAATGTTGAATGAGTGGG-3'), 200 &#956;M of each dNTPs, 2 &#956;l of 10 x reaction buffer (Takara Shuzo Co., Kyoto, Japan); and 1 unit of Taq DNA polymerase (Takara Shuzo Co.). Thirty PCR cycles of 30 sec at 94&#176;C, 30 sec at 61&#176;C, and 30 sec at 72&#176;C were performed. The amplified fragments were analyzed by electrophoresis with an automatic DNA sequencer with 8% or 6% polyacrylamide gels containing 7 M Urea (Amersham Pharmacia Biotech, Buckingamshire, UK). The raw data were converted to dinucleotide repeat polymorphic band patterns with the use of a software program (Amersham Pharmacia Biotech). The number of CA repeats in each amplified product was determined by comparison with a ladder of control DNAs.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>14596</offset><text>Statistical Analyses</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14617</offset><text>Comparisons between the various alleles in patients with AITDs and in controls were made with the &#935;2- test. Fisher's exact test was used when necessary. The relative risk was calculated by Woolf's method. Comparison of BMD in Z scores and biochemical markers between the group of individuals possessing one or two alleles of the genotype and the group without that genotype were performed using Student's t test. A P value less than 0.05 was considered statistically significant.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>15099</offset><text>Pre-publication history</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>15123</offset><text>The pre-publication history for this paper can be accessed here:</text></passage><passage><infon key="fpage">1</infon><infon key="name_0">surname:Ban;given-names:Y</infon><infon key="name_1">surname:Taniyama;given-names:M</infon><infon key="name_2">surname:Tozaki;given-names:T</infon><infon key="name_3">surname:Tomita;given-names:M</infon><infon key="name_4">surname:Ban;given-names:Y</infon><infon key="pub-id_doi">10.1186/1471-2350-1-1</infon><infon key="pub-id_pmid">11114845</infon><infon key="section_type">REF</infon><infon key="source">BMC Med Genet</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">2000</infon><offset>15188</offset><text>Estrogen receptor alpha dinucleotide repeat polymorphism in Japanese patients with autoimmune thyroid diseases.</text></passage><passage><infon key="fpage">63</infon><infon key="lpage">70</infon><infon key="name_0">surname:Tomer;given-names:Y</infon><infon key="name_1">surname:Barbesino;given-names:G</infon><infon key="name_2">surname:Greenberg;given-names:DA</infon><infon key="name_3">surname:Davies;given-names:TF</infon><infon key="pub-id_doi">10.1016/S1043-2760(96)00266-4</infon><infon key="section_type">REF</infon><infon key="source">Trends Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1997</infon><offset>15300</offset><text>The immunogenetics of autoimmune diabetes and autoimmune thyroid disease.</text></passage><passage><infon key="fpage">107</infon><infon key="lpage">120</infon><infon key="name_0">surname:Tomer;given-names:Y</infon><infon key="name_1">surname:Davies;given-names:TF</infon><infon key="pub-id_doi">10.1210/er.14.1.107</infon><infon key="pub-id_pmid">8491150</infon><infon key="section_type">REF</infon><infon key="source">Endocr Rev</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">1993</infon><offset>15374</offset><text>Infection, thyroid disease and autoimmunity.</text></passage><passage><infon key="fpage">537</infon><infon key="lpage">562</infon><infon key="name_0">surname:DeGroot;given-names:LJ</infon><infon key="name_1">surname:Quintans;given-names:J</infon><infon key="pub-id_pmid">2693084</infon><infon key="section_type">REF</infon><infon key="source">Endocr Rev</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">1989</infon><offset>15419</offset><text>The causes of autoimmune thyroid disease.</text></passage><passage><infon key="fpage">646</infon><infon key="lpage">682</infon><infon key="name_0">surname:Mckenzie;given-names:JM</infon><infon key="name_1">surname:Zakarija;given-names:M</infon><infon key="section_type">REF</infon><infon key="source">In Endocrinology, 2nd ed Edited by Degroot LJ, Besser GM, Cahill GF, et al Philadelphia: Saunders,</infon><infon key="type">ref</infon><infon key="year">1988</infon><offset>15461</offset><text>Hyperthyroidism.</text></passage><passage><infon key="fpage">648</infon><infon key="lpage">657</infon><infon key="name_0">surname:Volpe;given-names:R</infon><infon key="section_type">REF</infon><infon key="source">In Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text Edited by Braverman LE, Utiger RD Philadelphia: Lippincott-Raven,</infon><infon key="type">ref</infon><infon key="year">1991</infon><offset>15478</offset><text>Graves' disease.</text></passage><passage><infon key="fpage">1569</infon><infon key="lpage">1574</infon><infon key="name_0">surname:Yanagawa;given-names:T</infon><infon key="name_1">surname:Mangklabruks;given-names:A</infon><infon key="name_2">surname:Chang;given-names:YB</infon><infon key="name_3">surname:Okamoto;given-names:Y</infon><infon key="name_4">surname:Fisfalen;given-names:ME</infon><infon key="name_5">surname:Curran;given-names:PG</infon><infon key="name_6">surname:DeGroot;given-names:LJ</infon><infon key="pub-id_doi">10.1210/jc.76.6.1569</infon><infon key="pub-id_pmid">8501164</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">76</infon><infon key="year">1993</infon><offset>15495</offset><text>Human histocompatibility leukocyte antigen DQA1 *0501 allele associated with genetic susceptibility to Graves' disease in a Caucasian population.</text></passage><passage><infon key="fpage">2112</infon><infon key="lpage">2117</infon><infon key="name_0">surname:Badenhoop;given-names:K</infon><infon key="name_1">surname:Walfish;given-names:PG</infon><infon key="name_2">surname:Rau;given-names:H</infon><infon key="name_3">surname:Fischer;given-names:S</infon><infon key="name_4">surname:Nicolay;given-names:A</infon><infon key="name_5">surname:Bogner;given-names:U</infon><infon key="name_6">surname:Schleusener;given-names:H</infon><infon key="name_7">surname:Usadel;given-names:KH</infon><infon key="pub-id_doi">10.1210/jc.80.7.2112</infon><infon key="pub-id_pmid">7608264</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">1995</infon><offset>15641</offset><text>Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease.</text></passage><passage><infon key="fpage">41</infon><infon key="lpage">45</infon><infon key="name_0">surname:Yanagawa;given-names:T</infon><infon key="name_1">surname:Hidaka;given-names:Y</infon><infon key="name_2">surname:Guimaraes;given-names:V</infon><infon key="name_3">surname:Soliman;given-names:M</infon><infon key="name_4">surname:DeGroot;given-names:LJ</infon><infon key="pub-id_doi">10.1210/jc.80.1.41</infon><infon key="pub-id_pmid">7829637</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">1995</infon><offset>15774</offset><text>CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population.</text></passage><passage><infon key="fpage">145</infon><infon key="lpage">148</infon><infon key="name_0">surname:Hill;given-names:SM</infon><infon key="name_1">surname:Fuqua;given-names:SAW</infon><infon key="name_2">surname:Chamness;given-names:GC</infon><infon key="name_3">surname:Greene;given-names:GL</infon><infon key="name_4">surname:McGuire;given-names:WL</infon><infon key="pub-id_pmid">2562795</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="year">1989</infon><offset>15858</offset><text>Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism.</text></passage><passage><infon key="fpage">77</infon><infon key="lpage">83</infon><infon key="name_0">surname:Yaich;given-names:L</infon><infon key="name_1">surname:Dupont;given-names:WD</infon><infon key="name_2">surname:Cavener;given-names:DR</infon><infon key="name_3">surname:Parl;given-names:FF</infon><infon key="pub-id_pmid">1345763</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">52</infon><infon key="year">1992</infon><offset>15994</offset><text>Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood.</text></passage><passage><infon key="fpage">439</infon><infon key="lpage">441</infon><infon key="name_0">surname:Lehrer;given-names:S</infon><infon key="name_1">surname:Rabin;given-names:J</infon><infon key="name_2">surname:Kalir;given-names:T</infon><infon key="name_3">surname:Schachter;given-names:BS</infon><infon key="pub-id_pmid">8458645</infon><infon key="section_type">REF</infon><infon key="source">Hypertension</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">1993</infon><offset>16145</offset><text>Estrogen receptor variant and hypertension in women.</text></passage><passage><infon key="fpage">306</infon><infon key="lpage">311</infon><infon key="name_0">surname:Kobayashi;given-names:S</infon><infon key="name_1">surname:Inoue;given-names:S</infon><infon key="name_2">surname:Hosoi;given-names:T</infon><infon key="name_3">surname:Ouchi;given-names:Y</infon><infon key="name_4">surname:Shraki;given-names:M</infon><infon key="name_5">surname:Orimo;given-names:H</infon><infon key="pub-id_pmid">8852941</infon><infon key="section_type">REF</infon><infon key="source"> J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1996</infon><offset>16198</offset><text>Association of bone mineral density with polymorphism of the estrogen receptor gene.</text></passage><passage><infon key="fpage">378</infon><infon key="lpage">383</infon><infon key="name_0">surname:Sano;given-names:M</infon><infon key="name_1">surname:Inoue;given-names:S</infon><infon key="name_2">surname:Hosoi;given-names:T</infon><infon key="name_3">surname:Ouchi;given-names:Y</infon><infon key="name_4">surname:Emi;given-names:M</infon><infon key="name_5">surname:Shiraki;given-names:M</infon><infon key="name_6">surname:Orimo;given-names:H</infon><infon key="pub-id_doi">10.1006/bbrc.1995.2787</infon><infon key="pub-id_pmid">8526937</infon><infon key="section_type">REF</infon><infon key="source">Biochem Biophys Res Commun</infon><infon key="type">ref</infon><infon key="volume">217</infon><infon key="year">1995</infon><offset>16283</offset><text>Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis.</text></passage><passage><infon key="fpage">134</infon><infon key="lpage">137</infon><infon key="name_0">surname:Ushiyama;given-names:T</infon><infon key="name_1">surname:Ueyama;given-names:H</infon><infon key="name_2">surname:Inoue;given-names:K</infon><infon key="name_3">surname:Nishioka;given-names:J</infon><infon key="name_4">surname:Ohkubo;given-names:I</infon><infon key="name_5">surname:Hukuda;given-names:S</infon><infon key="pub-id_pmid">9458216</infon><infon key="section_type">REF</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1998</infon><offset>16368</offset><text>Estrogen receptor gene polymorphism and generalized osteoarthritis.</text></passage><passage><infon key="fpage">7</infon><infon key="lpage">10</infon><infon key="name_0">surname:Ushiyama;given-names:T</infon><infon key="name_1">surname:Mori;given-names:K</infon><infon key="name_2">surname:Inoue;given-names:K</infon><infon key="name_3">surname:Huang;given-names:J</infon><infon key="name_4">surname:Nishioka;given-names:J</infon><infon key="name_5">surname:Hukuda;given-names:S</infon><infon key="pub-id_pmid">10343533</infon><infon key="section_type">REF</infon><infon key="source">Ann Rheum Dis</infon><infon key="type">ref</infon><infon key="volume">58</infon><infon key="year">1999</infon><offset>16436</offset><text>Association of oestrogen receptor gene polymorphisms with age at onset of rheumatoid arthritis.</text></passage><passage><infon key="fpage">49</infon><infon key="lpage">53</infon><infon key="name_0">surname:Mosselman;given-names:S</infon><infon key="name_1">surname:Polman;given-names:J</infon><infon key="name_2">surname:Dijkema;given-names:R</infon><infon key="pub-id_doi">10.1016/0014-5793(96)00782-X</infon><infon key="pub-id_pmid">8769313</infon><infon key="section_type">REF</infon><infon key="source">FEBS Lett</infon><infon key="type">ref</infon><infon key="volume">392</infon><infon key="year">1996</infon><offset>16532</offset><text> ER-beta: identification and characterization of a novel human estrogen receptor.</text></passage><passage><infon key="fpage">537</infon><infon key="lpage">541</infon><infon key="name_0">surname:Ogawa;given-names:S</infon><infon key="name_1">surname:Hosoi;given-names:T</infon><infon key="name_2">surname:Shiraki;given-names:M</infon><infon key="name_3">surname:Orimo;given-names:H</infon><infon key="name_4">surname:Emi;given-names:M</infon><infon key="name_5">surname:Muramatsu;given-names:M</infon><infon key="name_6">surname:Ouchi;given-names:Y</infon><infon key="name_7">surname:Inoue;given-names:S</infon><infon key="pub-id_doi">10.1006/bbrc.2000.2285</infon><infon key="pub-id_pmid">10708589</infon><infon key="section_type">REF</infon><infon key="source">Biochem Biophys Res Commun</infon><infon key="type">ref</infon><infon key="volume">269</infon><infon key="year">2000</infon><offset>16614</offset><text>Association of estrogen receptor &#946; gene polymorphism with bone mineral density.</text></passage><passage><infon key="fpage">4321</infon><infon key="lpage">4327</infon><infon key="name_0">surname:Tomer;given-names:Y</infon><infon key="name_1">surname:Barbesino;given-names:G</infon><infon key="name_2">surname:Greenberg;given-names:DA</infon><infon key="name_3">surname:Concepcion;given-names:E</infon><infon key="name_4">surname:Davies;given-names:TF</infon><infon key="pub-id_doi">10.1210/jc.83.12.4321</infon><infon key="pub-id_pmid">9851771</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">1998</infon><offset>16697</offset><text>Linkage analysis of candidate genes in autoimmune thyroid disease. III. Detailed analysis of chromosome 14 localizes GD-1 close to MNG-1.</text></passage><passage><infon key="fpage">889</infon><infon key="lpage">895</infon><infon key="name_0">surname:Evans;given-names:RM</infon><infon key="pub-id_pmid">3283939</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">240</infon><infon key="year">1988</infon><offset>16835</offset><text>The steroid and thyroid hormone receptor superfamily.</text></passage><passage><infon key="fpage">217</infon><infon key="lpage">226</infon><infon key="name_0">surname:Cutolo;given-names:M</infon><infon key="name_1">surname:Sulli;given-names:A</infon><infon key="name_2">surname:Seriolo;given-names:B</infon><infon key="name_3">surname:Accardo;given-names:S</infon><infon key="name_4">surname:Masi;given-names:AT</infon><infon key="pub-id_pmid">7656468</infon><infon key="section_type">REF</infon><infon key="source">Clin Exp Rheumatol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1995</infon><offset>16889</offset><text>Estrogens, the immune response and autoimmunity.</text></passage><passage><infon key="fpage">73</infon><infon key="lpage">74</infon><infon key="name_0">surname:Tsukamoto;given-names:K</infon><infon key="name_1">surname:Inoue;given-names:S</infon><infon key="name_2">surname:Hosoi;given-names:T</infon><infon key="name_3">surname:Orimo;given-names:H</infon><infon key="name_4">surname:Emi;given-names:M</infon><infon key="pub-id_doi">10.1007/s100380050043</infon><infon key="pub-id_pmid">9610005</infon><infon key="section_type">REF</infon><infon key="source">J Hum Genet</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1998</infon><offset>16938</offset><text>Isolation and radiation hybrid mapping of dinucleotide repeat polymorphism at the human estrogen receptor &#946; locus.</text></passage><passage><infon key="fpage">390</infon><infon key="lpage">395</infon><infon key="name_0">surname:Reed;given-names:PW</infon><infon key="name_1">surname:Davies;given-names:JL</infon><infon key="name_2">surname:Copeman;given-names:JB</infon><infon key="name_3">surname:Bennett;given-names:ST</infon><infon key="name_4">surname:Palmer;given-names:SM</infon><infon key="name_5">surname:Pritchard;given-names:LE</infon><infon key="name_6">surname:Gough;given-names:SCL</infon><infon key="name_7">surname:Kawaguchi;given-names:Y</infon><infon key="name_8">surname:Cordell;given-names:HJ</infon><infon key="name_9">surname:Balfour;given-names:KM</infon><infon key="pub-id_pmid">7920657</infon><infon key="section_type">REF</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1994</infon><offset>17056</offset><text>Chromosome-specific microsatellite sets for fluorescence-based, semi-automated genome mapping.</text></passage><passage><infon key="fpage">197</infon><infon key="lpage">202</infon><infon key="name_0">surname:Pritchard;given-names:LE</infon><infon key="name_1">surname:Kawaguchi;given-names:Y</infon><infon key="name_2">surname:Reed;given-names:PW</infon><infon key="name_3">surname:Copeman;given-names:JB</infon><infon key="name_4">surname:Davies;given-names:JL</infon><infon key="name_5">surname:Barnett;given-names:AH</infon><infon key="name_6">surname:Bain;given-names:SC</infon><infon key="name_7">surname:Todd;given-names:JA</infon><infon key="pub-id_pmid">7757067</infon><infon key="section_type">REF</infon><infon key="source">Hum Mol Genet</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">1995</infon><offset>17151</offset><text>Analysis of the CD3 region and type 1 diabetes: application of fluorescence-based technology to linkage disequilibrium mapping.</text></passage><passage><infon key="fpage">251</infon><infon key="lpage">255</infon><infon key="name_0">surname:Woolf;given-names:B</infon><infon key="pub-id_pmid">14388528</infon><infon key="section_type">REF</infon><infon key="source">Ann Hum Genet</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">1955</infon><offset>17279</offset><text>On estimating the relation between blood group and disease.</text></passage></document></collection>